The Sunnybrook stroke study : A prospective study of depressive symptoms and functional outcome

To assess the prevalence of depressive symptoms, their clinical correlates, and the effects of depressive symptoms on stroke recovery, a relatively unselected, well-diagnosed cohort of consecutive stroke survivors was followed prospectively. Consecutive admissions to a regional stroke center who met...

Full description

Saved in:
Bibliographic Details
Published in:Stroke (1970) 1998-03, Vol.29 (3), p.618-624
Main Authors: HERRMANN, N, BLACK, S. E, LAWRENCE, J, SZEKELY, C, SZALAI, J. P
Format: Article
Language:English
Subjects:
Activities of Daily Living
Aged
Biological and medical sciences
Cerebrovascular Disorders - complications
Depression - complications
Female
Humans
Male
Medical sciences
Neurology
Outcome Assessment (Health Care)
Prognosis
Prospective Studies
Vascular diseases and vascular malformations of the nervous system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the prevalence of depressive symptoms, their clinical correlates, and the effects of depressive symptoms on stroke recovery, a relatively unselected, well-diagnosed cohort of consecutive stroke survivors was followed prospectively. Consecutive admissions to a regional stroke center who met World Health Organization and National Institute of Neurological Disorders and Stroke criteria for stroke were eligible. Subarachnoid hemorrhage and brain stem strokes were excluded. Patients underwent CT, single-photon emission CT, and standardized neurological and cognitive examinations at entry. At 3 months and 1 year after stroke, depressive symptoms were assessed with the Montgomery Asberg Depression Rating Scale (MADRS) and the Zung Self-Rating Depression Scale (SDS). Functional outcome was measured with the Functional Independence Measure, and handicap was assessed by the Oxford Handicap Scale. We assessed 436 patients at entry (mean +/- SD age, 74.9 +/- 11.6 years). There were 150 patients available for assessment at 3 months and 136 at 1 year. Marked depressive symptoms were noted in 22% (SDS) to 27% (MADRS) at 3 months and 21% (SDS) to 22% (MADRS) at 1 year. Patents with marked depressive symptoms had more neurological impairment (P
ISSN:0039-2499
1524-4628
DOI:10.1161/01.STR.29.3.618